Many aspects of vaccine development, efficacy and safety deserve the utmost of attention as unparalleled progress in this regard occurs at breakneck speed for COVID-19. Aspects of vaccine safety that proportionately lack discussion even publicly in the scientific arena, whether inadvertently or purposely, are the issues of mutagenesis or oncogenesis. As Ball suggests, anti-vaccine postures will arise and potentially gain momentum in the context of a general hesitation for vaccination among some in the populace (1). Any damage done in the SARS-CoV-2 vaccine movement will undoubtedly be seen by some as collateral damage to the general concept of vaccination, especially if it is understood that corners will be cut for expediency. It is imperative, therefore, to ensure that a more comprehensive view of vaccine safety is well discussed, if not acted on, at least initially in scientific fora. As generally known, there are many approaches currently being investigated for SARS-CoV-2 vaccine development. Some of these, although not necessarily new, will be brought to clinical application and may include such new products as mRNA vaccines, plasmid or similar DNA constructs, and different virus-based carrier systems in the least. Safety will undoubtedly be analysed for short- or intermediate-term adverse effects. Will any such study, whether Phases 1, 2, or 3, be of sufficient number and timing to understand any opportunity for cellular transformation?

中文翻译：

---

疫苗载体的初步关注

疫苗开发，功效和安全性的许多方面都应引起高度重视，因为在这方面，COVID-19的发展速度惊人。无论是无意还是有意地，甚至在科学领域中，甚至在公众场合都缺乏讨论的疫苗安全性方面是诱变或致癌问题。正如鲍尔（Ball）所建议的那样，在民众中有些人普遍不愿进行疫苗接种的情况下，会出现反疫苗的姿势，并有可能获得动力（1）。毫无疑问，在SARS-CoV-2疫苗运动中造成的任何损害都将被视为对一般疫苗接种概念的附带损害，尤其是如果人们认为为方便起见，将偷工减料。因此，如果不采取行动，必须确保充分讨论疫苗安全性的更全面观点，至少最初是在科学论坛上。众所周知，目前正在研究许多用于SARS-CoV-2疫苗开发的方法。其中一些虽然不一定是新的，但将投入临床应用，并且可能至少包括诸如mRNA疫苗，质粒或类似的DNA构建体以及不同的基于病毒的载体系统之类的新产品。毫无疑问，将对安全性进行短期或中期不利影响分析。这样的研究（无论是1期，2期还是3期）是否有足够的数量和时间来了解细胞转化的机会？将被应用于临床，并且至少包括诸如mRNA疫苗，质粒或类似的DNA构建体以及不同的基于病毒的载体系统之类的新产品。毫无疑问，将对安全性进行短期或中期不利影响分析。这样的研究（无论是1期，2期还是3期）是否有足够的数量和时间来了解细胞转化的机会？将被应用于临床，并且至少包括诸如mRNA疫苗，质粒或类似的DNA构建体以及不同的基于病毒的载体系统之类的新产品。毫无疑问，将对安全性进行短期或中期不利影响分析。这样的研究（无论是1期，2期还是3期）是否有足够的数量和时间来了解细胞转化的机会？